Loading
Protein Degradation and Inhibitors · Journal article
Medicinal Research Reviews · September 7, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review of molecular glue degraders, an emerging class of small-molecule allosteric modulators that redirect E3 ligases to degrade previously intractable proteins. The paper synthesizes mechanistic principles, discovery strategies, and challenges, but reports no clinical trial results, efficacy endpoints, or comparative data; it identifies gaps and research priorities in the field rather than quantifying therapeutic benefit.
Journal article.
Molecular glue degraders function by redirecting E3 ligases to recognize neosubstrates—proteins not typically targeted by specific E3 ligases—expanding the scope of protein degradation therapy Key mechanistic principles include cooperativity, weak affinity interactions, structural degrons, and higher-order complex formation Major challenges identified: resistance mechanisms, context-dependent activity, and limitations in predicting neosubstrates
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
This is a mechanistic review of an emerging drug class with no clinical efficacy data, preclinical results, or trial outcomes reported; it raises scientific questions about molecular glue degraders rather than answering them with evidence.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Molecular glue degraders are an emerging class of small molecule allosteric modulators that induce or stabilize protein-protein interactions, enabling targeted degradation of previously intractable proteins. By redirecting E3 ligases to recognize neosubstrates, proteins that are not typically recognized by a specific E3 ubiquitin ligase, they expand the scope of drug discovery beyond traditional paradigms. We review mechanistic principles underlying molecular glue activity, including cooperativity, weak affinity interactions, structural degrons, and higher-order complex formation. We discuss discovery strategies, from serendipitous identification to emerging rational and chemoproteomic approaches, and key E3 ligase systems with relevance to oncology. We highlight clinical and preclinical applications, alongside challenges such as resistance mechanisms, context-dependent activity, and limitations in predicting neosubstrates. Molecular glues are transitioning from serendipitous discoveries to a mechanism-driven therapeutic platform. Progress depends on integrating structural biology, proteomics, and computational modeling to enable rational design and improve predictability. Expanding the repertoire of E3 ligases and understanding context-specific degradation will be critical to fully realize their potential in oncology and beyond.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.